Ontology highlight
ABSTRACT:
SUBMITTER: Carlino MS
PROVIDER: S-EPMC5528644 | biostudies-literature | 2014 May
REPOSITORIES: biostudies-literature
Molecular oncology 20140115 3
Acquired resistance to BRAF inhibitors often involves MAPK re-activation, yet the MEK inhibitor trametinib showed minimal clinical activity in melanoma patients that had progressed on BRAF-inhibitor therapy. Selective ERK inhibitors have been proposed as alternative salvage therapies. We show that ERK inhibition is more potent than MEK inhibition at suppressing MAPK activity and inhibiting the proliferation of multiple BRAF inhibitor resistant melanoma cell models. Nevertheless, melanoma cells o ...[more]